{"id":11353,"date":"2016-04-12T12:00:04","date_gmt":"2016-04-12T12:00:04","guid":{"rendered":"http:\/\/i-base.info\/guides\/?p=11353"},"modified":"2024-08-30T14:05:34","modified_gmt":"2024-08-30T14:05:34","slug":"genvoya-elvitegravir-cobicistat-emtricitabine-ftc-taf","status":"publish","type":"post","link":"https:\/\/i-base.info\/guides\/11353","title":{"rendered":"Genvoya: elvitegravir + cobicistat + emtricitabine + TAF (E\/C\/F\/TAF)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-11360\" src=\"https:\/\/i-base.info\/guides\/wp-content\/uploads\/2016\/04\/genvoya-510-side.png\" alt=\"genvoya 510 side\" width=\"100\" height=\"67\" \/><\/p>\n<p><!--more--><\/p>\n<p><em>jen-VOY-uh<\/em><\/p>\n<p>Genvoya\u00a0is a single pill that contains elvitegravir\u00a0(150 mg) the booster cobicistat (150 mg) emtricitabine (200 mg) and tenofovir alafenamide fumarate (10 mg). It is a white\/grey tablet.<\/p>\n<p><strong>Geneva\u00a0is approved by the EMA in Europe and by the FDA in the US.\u00a0<\/strong><\/p>\n<p><strong>Genvoya<\/strong>\u00a0is a 4-in-1 single combination pill that is\u00a0taken once-daily, with food.<\/p>\n<p>The active drugs in Genvoya\u00a0are:<\/p>\n<ul>\n<li>150 mg\u00a0<a href=\"https:\/\/i-base.info\/guides\/8928\">elvitegravir<\/a><em>\u00a0&#8211;\u00a0an integrase inhibitor.<\/em><\/li>\n<li>150 mg\u00a0<a href=\"https:\/\/i-base.info\/guides\/8930\">cobicistat<\/a><em>\u00a0&#8211;\u00a0a \u201cbooster\u201d for elvitegravir.<\/em><\/li>\n<li>10 mg\u00a0<a href=\"https:\/\/i-base.info\/guides\/11059\">tenofovir alafenamide (TAF)<\/a><\/li>\n<li>200 mg\u00a0<a href=\"https:\/\/i-base.info\/guides\/3535\">FTC<\/a>.<\/li>\n<\/ul>\n<p>Other important characteristics include:<\/p>\n<ul>\n<li>Genvoya needs to be taken with food. The amount of type of food is not included in this recommendation but it may be important to include fat. The food interaction study reported that\u00a0elvitegravir exposure (total drug levels over the dose period, called the AUC) increased by 36% with a light meal (~373 kcal, 20% fat)\u00a0and by 91% with a high-fat meal (~800 kcal, 50% fat).<\/li>\n<li><strong>Drug interactions<\/strong> include with antacid medicines which can reduce levels of elvitegravir. Antacids need to be be separated by at least four hours.<\/li>\n<li>A potential interaction means that multivitamins and elvitegravir need to be separated by at least four hours.<\/li>\n<li><strong>Drug interactions. <\/strong>Please tell your doctor or pharmacist about any other drugs or supplements before taking them with Genvoya. Drug interactions can also be checked using the online checker at Liverpool University HIV Interaction website:<br \/>\n<a href=\"https:\/\/www.hiv-druginteractions.org\/checker\">https:\/\/www.hiv-druginteractions.org\/checker<\/a><\/li>\n<li>Genvoya should not be used in people with reduced kidney function defined as having eGRF levels less than 30 mL\/minute.<\/li>\n<li>Genvoya should not be used in people with severe liver impairment.<\/li>\n<li>The US\u00a0approval included a second formulation that used a 25 mg dose of TAF. In the US, the 25 mg TAF version is recommended when used in combinations that do not included boosted protease inhibitors.<\/li>\n<\/ul>\n<p>The European\u00a0<em>patient leaflet<\/em>\u00a0and detailed\u00a0<em>Product Information<\/em>\u00a0for Genvoya are available <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/genvoya\">at this link<\/a> on the European Medicines Agency (EMA) website.<\/p>\n<p>The\u00a0<em>Patient Information<\/em>\u00a0is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.<\/p>\n<p>The\u00a0<em>Product Information<\/em>\u00a0is a detailed technical summary that you can access as a PDF file by clicking the \u2018Product Information\u2019 tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.<\/p>\n<p>Link to\u00a0EU prescribing information. (html pages)<\/p>\n<p>Link to\u00a0<a href=\"http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/genvoya\/genvoya_pi.pdf\" target=\"_blank\" rel=\"noopener\">US prescribing information<\/a>. (PDF document)<\/p>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,6,8,10,14],"tags":[],"class_list":["post-11353","post","type-post","status-publish","format-standard","hentry","category-arvs","category-fixed-dose-combinations","category-integrase-inhibitors","category-nukes","category-pk-booster"],"_links":{"self":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts\/11353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/comments?post=11353"}],"version-history":[{"count":2,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts\/11353\/revisions"}],"predecessor-version":[{"id":17226,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts\/11353\/revisions\/17226"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/media?parent=11353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/categories?post=11353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/tags?post=11353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}